Autopsy report · NCT01489046
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Cause of deathNo reason given
Life of this trial
- Registered 10 months after it had already started.
- Ran for about 3 years 5 months before it stopped.
- 297 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry
- Conditions
- HIV-1 Infection
- Interventions
- BMS-986001; BMS-986001; BMS-986001; Placebo matching with BMS-986001; Efavirenz; Lamivudine
- Participants
- 297
- Sites
- 51
- Countries
- Argentina, Australia, Canada, Chile, Colombia, France, Hungary, Mexico, Peru, South Africa, Spain, Thailand and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.